

Special Issue

Mitochondria Metabolism and Cancer Therapy

Message from the Guest Editors

Cancer is one of the most devastating and intractable diseases. Alterations of cellular metabolism, in particular of glycolysis and mitochondrial metabolism, are recognized hallmarks of most types of cancer.

Adaptation of the cellular metabolism in cancer provides the necessary energy and building blocks for cell proliferation. Mitochondria also regulate redox and calcium homeostasis, participate in transcriptional regulation, and govern cell death. Therefore, therapies targeting diverse mitochondrial metabolic functions have emerged as a novel potent option to enhance the efficacy of established anti-cancer treatments such as radio- and chemotherapy as well as immunotherapy.

This Special Issue of *Cancers* will include the latest research on mitochondrial metabolism in cancer and the cancer microenvironment with a focus on the therapeutic potential of targeting mitochondrial metabolism for cancer therapy.

Guest Editors

Prof. Dr. Barbara Kofler

Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, 5020 Salzburg, Austria

Prof. Dr. Marie Arsenian-Henriksson

Karolinska Institutet, Department of Microbiology, Tumor and Cell Biology, Nobelsväg 16, 17177 Stockholm, Sweden

Deadline for manuscript submissions

closed (31 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/38677

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)